No Data
No Data
Buy Rating Affirmed for ArriVent BioPharma on Strong Drug Trial Prospects and Strategic Advancements
ArriVent BioPharma Welcomes Dr. Hohneker to Board
Press Release: ArriVent Appoints John Hohneker, M.D., to Its Board of Directors
ArriVent BioPharma today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics.
The top four private equity firms revealed the “US stock report card”: Pinduoduo is still proud of Gao Yi and Gao Yi, but Jing Lin quietly reduced its positions
① The latest moves by Chinese private equity institutions such as Gao Yi, Gao Yi, Jing Lin, and Himalaya have recently been revealed; ② Overall, Chinese securities are still popular among Chinese institutions, especially Pinduoduo, and are also famous in the leading positions of Gao Yi, Gao Yi, and Jing Lin; ③ However, Jing Lin drastically reduced its holdings of Pinduo by 1.1 million shares in the first quarter, which is at odds with Gao Yu and Gao Yi's move to increase positions.
HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $25 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $25 price target.
Buy Rating for ArriVent BioPharma Amid Strong Financials and Promising Clinical Trials
No Data